These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Etanercept for psoriasis: two case reports. Fidalgo A; Baptista J; Rocha Páris F; Caldas Lopes L; Ferreira A Int J Clin Pharmacol Res; 2005; 25(4):159-63. PubMed ID: 16402631 [TBL] [Abstract][Full Text] [Related]
45. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study. Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557 [TBL] [Abstract][Full Text] [Related]
46. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908 [TBL] [Abstract][Full Text] [Related]
49. [Clinical experience with etanercept in the treatment of psoriasis]. Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167 [TBL] [Abstract][Full Text] [Related]
50. Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation. Moutsopoulos NM; Katsifis GE; Angelov N; Leakan RA; Sankar V; Pillemer S; Wahl SM Ann Rheum Dis; 2008 Oct; 67(10):1437-43. PubMed ID: 18198195 [TBL] [Abstract][Full Text] [Related]
51. Etanercept: a review of its use in rheumatoid arthritis. Jarvis B; Faulds D Drugs; 1999 Jun; 57(6):945-66. PubMed ID: 10400407 [TBL] [Abstract][Full Text] [Related]
52. [Anti-TNF alpha agents in vasculitis]. Solans Laqué R; Bosch Gil JA Med Clin (Barc); 2008 Feb; 130(3):93-4. PubMed ID: 18261379 [No Abstract] [Full Text] [Related]
53. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. Tobinick EL; Gross H BMC Neurol; 2008 Jul; 8():27. PubMed ID: 18644112 [TBL] [Abstract][Full Text] [Related]
54. The use of etanercept in a patient with disseminated tuberculosis. Kim JY; Park JN; Lee JG; Lee YA; Kim YH; Hong SJ; Yang HI; Lee SH Rheumatol Int; 2009 Sep; 29(11):1377-80. PubMed ID: 19151979 [TBL] [Abstract][Full Text] [Related]
55. Long-term experience with etanercept in psoriatic arthritis patients: a 3-year observational study. Mazzotta A; Esposito M; Schipani C; Chimenti S J Dermatolog Treat; 2009; 20(6):354-8. PubMed ID: 19954392 [TBL] [Abstract][Full Text] [Related]
56. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. de Vlam K; Lories RJ Rheumatology (Oxford); 2006 Mar; 45(3):321-4. PubMed ID: 16234275 [TBL] [Abstract][Full Text] [Related]
57. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Martínez-Abundis E; Reynoso-von Drateln C; Hernández-Salazar E; González-Ortiz M Arch Dermatol Res; 2007 Nov; 299(9):461-5. PubMed ID: 17726611 [TBL] [Abstract][Full Text] [Related]
58. [Etanercept. An effective TNF alpha-antagonist in the treatment of psoriatic arthritis and chronic plaque psoriasis]. Wozel G Hautarzt; 2005 Sep; 56(9):819-30. PubMed ID: 16133634 [TBL] [Abstract][Full Text] [Related]